Vitruvia Medical Past Earnings Performance
Past criteria checks 0/6
Vitruvia Medical has been growing earnings at an average annual rate of 47.9%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been declining at an average rate of 48.7% per year.
Key information
47.9%
Earnings growth rate
34.1%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | -48.7% |
| Return on equity | n/a |
| Net Margin | -30.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vitruvia Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -1 | 1 | 0 |
| 30 Sep 23 | 2 | -1 | 2 | 0 |
| 30 Jun 23 | 2 | -2 | 2 | 0 |
| 31 Mar 23 | 2 | -2 | 2 | 0 |
| 31 Dec 22 | 2 | -1 | 2 | 0 |
| 30 Jun 22 | 1 | -7 | 0 | 0 |
| 31 Mar 22 | 2 | -7 | 1 | 0 |
| 31 Dec 21 | 2 | -8 | 2 | 0 |
| 31 Dec 20 | 6 | -2 | 3 | 0 |
Quality Earnings: 991 is currently unprofitable.
Growing Profit Margin: 991 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 991's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 991's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 991 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: 991's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.